Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.67 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.61 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10684470 | 0.87 | PTPN1 (0.88) | PTPN1MITFNPC1RAB9AMEN1 | |
| SCHEMBL15483230 | 0.84 | TRPV1 (0.69) | TRPV1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2560174 | 0.83 | TRPV1 (0.67) | TRPV1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20480843 | 0.83 | RAB9A (0.76) | TRPV1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28259723 | 0.83 | POLB (0.76) | TRPV1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL177468 | 0.82 | TRPV1 (0.81) | PTPN1TRPV1NPC1RAB9AMEN1 | |
| SCHEMBL387376 | 0.82 | TRPV1 (0.81) | PTPN1TRPV1NPC1RAB9AMEN1 | |
| SCHEMBL2556548 | 0.82 | NPC1 (0.71) | TRPV1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8770854 | 0.82 | PTPN1 (0.79) | PTPN1MITFNPC1RAB9AMEN1 | |
| SCHEMBL8768807 | 0.82 | MEN1 (0.86) | PTPN1MITFNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | MAP2K5, MAP2K7, MAP2K2 | PTPN1 846/4885TRPV1 3508/4885MITF 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.